FDA Approves Expanded Use for Biologic Autoinflammatory Disease Drug

Article

Ilaris is the first FDA-approved biologic treatment for Tumor Necrosis Factor–Receptor Associated Periodic Syndrome, Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency and Familial Mediterranean Fever.

Novartis has received 3 FDA approvals for the expanded use of Ilaris, also known as canakinumab, to treat distinct types of Periodic Fever Syndromes. Periodic Fever Syndromes are a group of rare autoinflammatory diseases that cause disabling and persistent fevers. They are accompanied by joint pain, swelling, muscle pain, and skin rashes with potentially life-threatening complications in some patients.

Ilaris is the first FDA-approved biologic treatment for Tumor Necrosis Factor—Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) and Familial Mediterranean Fever (FMF).

Ilaris is a selective, high-affinity, human monoclonal antibody that inhibits the Interleukin-1 beta in the body, which is critical to the body’s immune system defense. When the body excessively produces IL-1 beta in the body, it can contribute to certain inflammatory diseases.

“Gaining 3 simultaneous FDA approvals of Ilaris is a momentous turning point for people who suffer with these severe, debilitating diseases,” said Paul Hudson, CEO of Novartis, in a press release. “There is a significant unmet need in these conditions, particularly in children, and Novartis is proud to provide a new treatment option to those who so desperately need it.”

The FDA based its approval on results from the phase 3 CLUSTER study, which showed rapid and sustained disease control in patients who took Ilaris compared to a placebo. These results came after examining patients with TRAPS, HIDS/MKD or FMF through 16 weeks.

In clinical trials, the most common adverse effects linked to Ilaris were infections in the upper respiratory tract, some of which were serious.

Related Videos
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Krakenimages.com | stock.adobe.com
Human brain digital illustration. Electrical activity, flashes, and lightning on a blue background. | Image Credit: Siarhei - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.